SCHEMBL1779784

SCHEMBL1779784

CCOC(=O)c1ccc(C2CCC(C(F)(F)F)CC2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR2 Q92731 2/20 0.47
CA12 O43570 1/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
ESR1 P03372 1/20 0.47
CA7 P43166 1/20 0.47
CA9 Q16790 1/20 0.47
CA14 Q9ULX7 1/20 0.47
RAB9A P51151 2/20 0.47
LMNA P02545 2/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
MAOA P21397 1/20 0.46
FDFT1 P37268 1/20 0.46
CYP2C9 P11712 1/20 0.45
MAPT P10636 4/20 0.44
ALDH1A1 P00352 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
PDK1 Q15118 1/20 0.44
PDK2 Q15119 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1782299 1.00 ESR2 (0.47) ESR2CA12CA1CA2ESR1
SCHEMBL1779783 1.00 ESR2 (0.47) ESR2CA12CA1CA2ESR1
SCHEMBL4003420 0.88 CA12 (0.59) ESR2CA12CA1CA2ESR1
SCHEMBL28022173 0.82 FDFT1 (0.53) ESR2CA12CA1CA2ESR1
SCHEMBL21656823 0.81 MAPT (0.53) ESR2CA12CA1CA2ESR1
SCHEMBL3289949 0.81 LMNA (0.54) ESR2CA12CA1CA2ESR1
SCHEMBL1789154 0.81 ALDH1A1 (0.63) ESR2CA12CA1CA2ESR1
SCHEMBL24213928 0.79 FDFT1 (0.50) ESR2CA12CA1CA2ESR1
SCHEMBL604022 0.79 ESR2 (0.49) ESR2CA12CA1CA2ESR1
SCHEMBL601278 0.79 ESR2 (0.49) ESR2CA12CA1CA2ESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2197551-B1 SOLUBLE GUANYLATE CYCLASE ACTIVATORS MERCK SHARP & DOHME (US) 2016-12-28 EP disclosed
US-8455638-B2 Soluble guanylate cyclase activators MERCK SHARP & DOHME CORP. (US) 2013-06-04 US disclosed
US-20110118282-A1 Soluble Guanylate Cyclase Activators MERCK SHARP & DOHME LLC 2011-05-19 US disclosed
US-20090209556-A1 SOLUBLE GUANYLATE CYCLASE ACTIVATORS MERCK SHARP & DOHME CORP. 2009-08-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118282-A1 Soluble Guanylate Cyclase Activators GUCY1B1, GUCY1A2, GUCY1A1 ESR2 823/4885CA12 4835/4885CA1 4658/4885
US-20090209556-A1 SOLUBLE GUANYLATE CYCLASE ACTIVATORS GUCY1B1, GUCY1A2, GUCY1A1 ESR2 823/4885CA12 4835/4885CA1 4658/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.